Advanced SURF301 Phase 1 oncology study; Initial Phase 1 results to be reported in 2H 2024 TYRA-300 Phase 2 ACH IND submission on track for 2H 2024 Initiated SURF201 Phase 1 study and dosed first patient with TYRA-200 Strengthened balance sheet with approximately $200 million PIPE in Q1 2024; pro-forma cash, cash equivalents, and marketable securities of approximately $403.5 million CARLSBAD, Calif. , March 19, 2024... Read More